Assessing Particle Size in DPIs with Spraytec & Unidose

Assess setups to combine Spraytec & Unidose™ for evaluating particle size distribution in dry powder inhalers.

Pulmonary Fate of Fluticasone: Challenges Met

Nanopharm investigate the pulmonary effect of Fluticasone and related compounds, addressing physiologic and pharmacokinetic challenges.

In Vitro System for Orally Inhaled Drug Release

Discover the development of an in vitro dissolution and release system from Nanopharm for OINDPs (orally inhaled drug products).

Regional Deposition in Generic Dry Powder Inhalers

Nanopharm investigate regional deposition and simulated inhaled pharmacokinetic profiles of generic dry powder inhalers.

Faster, Cost-Effective Alternative to Generic Bioequivalence

Discover SmartTrack to advance the development of OINDPs. Streamline inhalation and nasal therapies with optimized particle size distribution.

Mixed Kinetic Model of Inhaled Corticosteroid Dissolution

Explore the dissolution kinetics of inhaled pharmaceuticals in dry powder inhalers (DPI) and pressurized metered dose inhalers (pMDI).

Automated Classification of DPI Agglomerate Particles

Explore automated classification of dry powder inhaler particles using Cluster Analysis and Morphologically Directed Raman Spectroscopy.

Alternative regulatory path for generic Respiratory Products

Explore Nanopharm’s SmartTrack, an alternative solution for FDA approval of generic inhalation drug delivery products.

Challenges in OINDPs Achieving Q3 Equivalence

Nanopharm review the bioequivalence challenges for OINDPs by achieving Q3 structural equivalence.

Trade Marks Registration Certificate for Nanopharm Ltd

Discover Nanopharm’s leading role in pharmaceutical research, specializing in OINDP, nasal, and inhaled pharmaceutical solutions.